NIKI
Niki BioSolutions Inc.
NIKI | NASDAQ
$1.70
-$0.07 (-3.95%)
Nov 2, 2026, 9:32 AM ET · Market open
Company Profile
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
Key Executives
| Name | Position |
|---|---|
| Chung Yuen Huen | Founder, Executive Chairman & CEO |
| Alidad Mireskandari | President, COO & Board Observer |
| Kwok Kuen Wong | Head of Finance |
Niki BioSolutions Inc.
NIKI
| Country | United States |
| IPO Date | Jul 20, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Chung Yuen Huen |
Contact Details
116 Village Boulevard, Suite 200 Princeton,
New Jersey 08540 United States
Stock Details
| Ticker Symbol | NIKI |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001734005 |
| CUSIP Number | 653942102 |
| ISIN Number | US6539421023 |
| SIC Code | n/a |
Add to Watchlist
Select watchlists to add or remove NIKI